We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Trial watch: novel antiarrhythmic agent shows promise in Phase III trial.
- Abstract
The article focuses on the study on Phase III ATHENA dronedarone trial that is used for treating atrial fibrillation. Accordingly, the dronedarone is a drug from the Sanofi-Aventis U.S. LLC that can be used to maintain sinus rhythm and manipulate ventricular rate on the reoccurrences of atrial fibrillation. ATHENA was applied to measure the safety and efficacy of dronedarone to patients. Moreover, Sanofi-Aventis has passed a new drug application to the U.S. Food and Drug Administration (FDA).
- Subjects
UNITED States; ATRIAL fibrillation treatment; SANOFI-Aventis US LLC; VENTRICULAR fibrillation; DRUG utilization; UNITED States. Food &; Drug Administration
- Publication
Nature Reviews Drug Discovery, 2009, Vol 8, Issue 4, p266
- ISSN
1474-1776
- Publication type
journal article
- DOI
10.1038/nrd2860